SCHEMBL6285571

SCHEMBL6285571

COc1ccc(S(=O)(=O)n2cc(/C(C)=N\NC(=N)N)c3ccccc32)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 8/20 0.55
PDE4A P27815 2/20 0.47
PDE4B Q07343 2/20 0.47
PDE4C Q08493 2/20 0.47
PDE4D Q08499 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PLK1 P53350 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
HCRTR1 O43613 1/20 0.41
ALOX5 P09917 1/20 0.41
AKR1C3 P42330 1/20 0.40
AKR1C1 Q04828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285576 1.00 HTR6 (0.55) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6278507 0.88 HTR6 (0.52) HTR6MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6278510 0.88 HTR6 (0.52) HTR6MEN1KMT2ALMNASMN1; SMN2
SCHEMBL6278516 0.88 HTR6 (0.45) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6278518 0.88 HTR6 (0.45) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6286983 0.88 HTR6 (0.45) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6286990 0.88 HTR6 (0.45) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6281048 0.86 HTR6 (0.51) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6281043 0.86 HTR6 (0.51) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6284042 0.86 HTR6 (0.53) HTR6PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A HTR6 1/4885PDE4A 1140/4885PDE4B 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.